Aditus Medical

Aditus Medical

Munich, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $18M

Overview

Aditus Medical is a private, commercial-stage medical device company specializing in synthetic bone graft substitutes. Its product portfolio, which appears to be approved and commercially available, targets the orthopedic and spinal surgery markets, aiming to address bone void filling needs. The company employs a direct commercialization strategy, participating in major international trade shows like MEDICA and Arab Health to build partnerships and expand its global footprint. Founded in 2016, it operates from Munich, Germany, and is positioned in the competitive but growing biomaterials segment of the medical device industry.

OrthopedicsSpinal Surgery

Technology Platform

Synthetic bone graft substitute materials formulated into multiple delivery forms (Granules, Gel, Putty, Stick) for bone void filling in orthopedic and spinal procedures.

Funding History

2
Total raised:$18M
Series A$15M
Seed$3M

Opportunities

The global bone graft substitute market offers significant growth potential driven by demographic trends and a preference for synthetic materials over autografts.
Aditus's multi-format product portfolio allows it to address diverse surgical needs, providing a competitive edge.
Targeted expansion into growth regions like the MENA area through events like Arab Health presents a clear geographic opportunity.

Risk Factors

Intense competition from large, well-capitalized medical device corporations with dominant market shares poses a major threat.
The company's reliance on a single product category and lack of a visible next-generation pipeline creates vulnerability to market shifts.
Navigating complex and costly regulatory and reimbursement pathways in new international markets presents a significant operational and financial hurdle.

Competitive Landscape

Aditus competes in the crowded synthetic bone graft segment against major players like Medtronic, Stryker, Zimmer Biomet, and Smith & Nephew, as well as specialized biomaterial companies. Competition is based on product performance (handling, resorption rate), clinical data, price, and the strength of distributor relationships. The company's niche strategy relies on its focused product forms and direct engagement at surgical congresses to differentiate itself.